Humana Inc. (NYSE:HUM) Shares Sold by Metropolitan Life Insurance Co NY

Metropolitan Life Insurance Co NY trimmed its stake in shares of Humana Inc. (NYSE:HUM) by 2.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,445 shares of the insurance provider’s stock after selling 145 shares during the quarter. Metropolitan Life Insurance Co NY’s holdings in Humana were worth $2,435,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Sunbelt Securities Inc. acquired a new position in Humana in the first quarter worth about $28,000. Gradient Investments LLC grew its position in shares of Humana by 50.0% in the 2nd quarter. Gradient Investments LLC now owns 69 shares of the insurance provider’s stock worth $31,000 after acquiring an additional 23 shares in the last quarter. Larson Financial Group LLC grew its position in shares of Humana by 81.0% in the 2nd quarter. Larson Financial Group LLC now owns 76 shares of the insurance provider’s stock worth $34,000 after acquiring an additional 34 shares in the last quarter. Beacon Capital Management LLC increased its holdings in shares of Humana by 87.0% in the 2nd quarter. Beacon Capital Management LLC now owns 86 shares of the insurance provider’s stock valued at $38,000 after acquiring an additional 40 shares during the last quarter. Finally, Mendota Financial Group LLC acquired a new stake in shares of Humana during the 2nd quarter valued at approximately $38,000. 91.86% of the stock is owned by institutional investors and hedge funds.

Humana Stock Performance

HUM stock opened at $501.79 on Tuesday. The company has a 50-day simple moving average of $497.71 and a 200 day simple moving average of $485.08. The company has a market capitalization of $61.78 billion, a P/E ratio of 20.80, a PEG ratio of 1.33 and a beta of 0.61. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.56. Humana Inc. has a fifty-two week low of $423.29 and a fifty-two week high of $558.04.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, November 1st. The insurance provider reported $7.78 EPS for the quarter, topping analysts’ consensus estimates of $7.15 by $0.63. The company had revenue of $26.42 billion for the quarter, compared to the consensus estimate of $25.57 billion. Humana had a net margin of 2.95% and a return on equity of 21.03%. Humana’s revenue was up 15.9% on a year-over-year basis. During the same period in the previous year, the firm earned $6.88 EPS. Sell-side analysts predict that Humana Inc. will post 28.28 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date is Thursday, December 28th. Humana’s payout ratio is currently 14.68%.

Analysts Set New Price Targets

HUM has been the subject of a number of research reports. Stephens decreased their price objective on shares of Humana from $575.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, November 2nd. Morgan Stanley lowered their price objective on shares of Humana from $637.00 to $624.00 and set an “overweight” rating for the company in a research report on Wednesday, August 30th. JPMorgan Chase & Co. cut their target price on shares of Humana from $593.00 to $575.00 and set a “neutral” rating on the stock in a report on Friday. TD Cowen decreased their target price on Humana from $616.00 to $613.00 and set an “outperform” rating for the company in a research note on Tuesday, August 15th. Finally, StockNews.com upgraded Humana from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 3rd. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $590.28.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.